SCHEDULE 13G/A: BlackRock Maintains Significant Stake in Corcept Therapeutics, Reports 10.9% Ownership

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, disclosing a 10.9% beneficial ownership stake in Corcept Therapeutics Incorporated as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 11,539,099 shares of Corcept Therapeutics Incorporated common stock.
• This holding represents 10.9% of the total outstanding common stock of Corcept Therapeutics Incorporated.
• BlackRock holds sole voting power over 11,314,797 shares and sole dispositive power over 11,539,099 shares.
• No shared voting or dispositive power was reported.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The event date requiring this filing was June 30, 2025.
• iShares Core S&P Small-Cap ETF and BlackRock Fund Advisors are identified as entities within BlackRock's structure that each beneficially own 5% or greater of Corcept Therapeutics' outstanding common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) reporting beneficial ownership by a large institutional investor. It contains factual information about shareholdings and does not convey positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral as it's a compliance-driven disclosure.

Positives

• BlackRock's continued significant stake (10.9%) in Corcept Therapeutics indicates ongoing institutional confidence in the company.

Risks

• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Corcept Therapeutics, mitigating the risk of an activist investor taking a stake.

Future Outlook

No forward-looking statements or guidance regarding Corcept Therapeutics' business or financial performance are provided in this beneficial ownership report.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11." (BlackRock, Inc. certification)

Industry Context

This filing reflects a large institutional asset manager's passive investment in a biotechnology/healthcare company. Such filings are routine for large funds managing diversified portfolios and indicate a standard investment position within the sector.

Comparison to Industry Standards

• BlackRock's 10.9% stake is a significant passive holding, typical for large index funds or actively managed funds with a long-term view in the healthcare sector.
• The filing adheres to standard SEC Schedule 13G requirements for reporting beneficial ownership by passive investors.
• The ownership by iShares Core S&P Small-Cap ETF indicates Corcept Therapeutics is part of a widely tracked small-cap index, which is a common investment vehicle for institutional investors.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, potentially reinforcing confidence due to BlackRock's continued investment.

Next Steps

• BlackRock, Inc. will file further amendments to this Schedule 13G if there are material changes to its beneficial ownership of Corcept Therapeutics Incorporated common stock.

Key Dates

Keywords

Corcept Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Healthcare, Biotechnology